Fig. 4From: Aspartate β-hydroxylase as a target for cancer therapyASPH as a therapeutic target. ASPH expression is upregulated by growth factors and hypoxia. Its enzymatic activity can be inhibited by SMIs or monoclonal antibodies which results in reduction of cell proliferation, angiogenesis, immunosuppression, and cell migration and invasion. Consequently, tumor growth and metastasis are also reducedBack to article page